- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04697784
Étude post-approbation du système d'endoprothèse abdominale TREO (TREO PAS)
Étude post-approbation du système d'endoprothèse abdominale TREO (P190015) chez des patients atteints d'anévrismes aortiques abdominaux sous-rénaux et aorto-iliaques
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.
The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006
- Vascular Surgery Specialists
-
Tucson, Arizona, États-Unis, 85718
- Pima Heart and Vascular
-
-
California
-
Fresno, California, États-Unis, 93701
- University of California, San Francisco-Fresno
-
La Jolla, California, États-Unis, 92037
- University of California, San Diego
-
San Diego, California, États-Unis, 92161
- VA San Diego
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- University of Colorado Anschutz
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06520
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Medstar Washington Hospital Center
-
-
Florida
-
Gainesville, Florida, États-Unis, 32610
- University of Florida
-
Gainesville, Florida, États-Unis, 32608
- Malcom Randall VA Medical Center
-
Pensacola, Florida, États-Unis, 32504
- Coastal Vascular and Interventional
-
Tampa, Florida, États-Unis, 33606
- University of South Florida / Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30342
- Northside Hospital
-
Atlanta, Georgia, États-Unis, 30309
- Piedmont Heart Institute
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa Hospital and Clinic
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, États-Unis, 02111
- Tufts Medical Center
-
-
Michigan
-
Bay City, Michigan, États-Unis, 48708
- McLaren Bay Region
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Barnes Jewish Hospital at Washington University
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, États-Unis, 08901
- Rutgers Robert Wood Johnson Medical Center
-
-
New York
-
New York, New York, États-Unis, 10075
- Lenox Hill Hospital / Northwell Health
-
Stony Brook, New York, États-Unis, 11794-8191
- Stony Brook Medical Center
-
Syracuse, New York, États-Unis, 13210
- SUNY Upstate Medical University
-
The Bronx, New York, États-Unis, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Asheville, North Carolina, États-Unis, 27607
- Mission Health
-
Greenville, North Carolina, États-Unis, 27834
- East Carolina University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health and Science University
-
Portland, Oregon, États-Unis, 97239
- VA Portland Healthcare System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Kingsport, Tennessee, États-Unis, 37660
- Wellmont Cardiology Services
-
-
Texas
-
Austin, Texas, États-Unis, 78756
- St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84132
- University of Utah Hospital
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 22042
- Sentara Heart Hospital
-
Richmond, Virginia, États-Unis, 23282
- Virginia Commonwealth University
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Willing and able to comply with all study procedures and visits.
- Written informed consent to participate in the study.
- Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
- Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.
Exclusion Criteria:
• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Subjects who receive the TREO Abdominal Stent-Graft System
Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System. |
The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
Délai: Through 5 Years post-procedure
|
Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies. |
Through 5 Years post-procedure
|
|
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
Délai: Through 5 Years post-procedure
|
Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies. |
Through 5 Years post-procedure
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with technical success at the conclusion of the index procedure
Délai: Through 5 Years post-procedure
|
Defined as the following:
|
Through 5 Years post-procedure
|
|
Major Adverse Events
Délai: Through 5 Years post-procedure
|
Incidence of the following Major Adverse Events
|
Through 5 Years post-procedure
|
|
Incidence of procedure-related clinical utility measures
Délai: Through 5 Years post-procedure
|
Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type. |
Through 5 Years post-procedure
|
|
Incidence of procedure-related complications
Délai: Through 5 Years post-procedure
|
Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related. |
Through 5 Years post-procedure
|
|
Incidence of successful aneurysm treatment
Délai: 12 months post-implant
|
Successful aneurysm treatment is defined as:
|
12 months post-implant
|
|
Incidence of all-cause mortality
Délai: Through 5 Years post-procedure
|
Rate of mortality attributed to any causality as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm-related mortality
Délai: Through 5 Years post-procedure
|
Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm rupture
Délai: Through 5 Years post-procedure
|
Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of secondary interventions.
Délai: Through 5 Years post-procedure
|
Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System |
Through 5 Years post-procedure
|
|
Incidence of conversion to open surgical repair.
Délai: Through 5 Years post-procedure
|
Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft occlusion (i.e., loss of patency)
Délai: Through 5 Years post-procedure
|
Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition. |
Through 5 Years post-procedure
|
|
Incidence of device stenosis or kink
Délai: Through 5 Years post-procedure
|
Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of loss of device integrity
Délai: Through 5 Years post-procedure
|
Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
Délai: Through 5 Years post-procedure
|
Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
Délai: Through 5 Years post-procedure
|
Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of Type I, II, III, IV or V Endoleaks
Délai: Through 5 Years post-procedure
|
Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab. |
Through 5 Years post-procedure
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Gretchen Wild, Terumo Aortic
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IP-0021-20
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .